Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
3.920
-0.010 (-0.25%)
At close: Jul 30, 2025, 4:00 PM
3.910
-0.010 (-0.26%)
After-hours: Jul 30, 2025, 7:59 PM EDT
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $8.72M in the quarter ending March 31, 2025, a decrease of -27.65%. This brings the company's revenue in the last twelve months to $54.23M, up 5.29% year-over-year. In the year 2024, Aquestive Therapeutics had annual revenue of $57.56M with 13.80% growth.
Revenue (ttm)
$54.23M
Revenue Growth
+5.29%
P/S Ratio
6.66
Revenue / Employee
$381,887
Employees
142
Market Cap
389.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AQST News
- 8 days ago - Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewsWire
- 15 days ago - Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film - GlobeNewsWire
- 23 days ago - Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - GlobeNewsWire
- 5 weeks ago - Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval - Seeking Alpha
- 5 weeks ago - Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share - Seeking Alpha
- 2 months ago - Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire